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To the Editor: In the study by Tentori et al.,1 even though the
crude mortality of dialysis patients who received vitamin D3
analog calcitriol was inferior to those who received either of
the two vitamin D2 analogs paricalcitol or doxercalciferol,
these differences were not statistically significant after
multivariate adjustment.1 In contrast, Teng et al.2 had
reported a robust survival advantage of vitamin D2
paricalcitol compared with vitamin D3 calcitriol irrespective
of multivariate adjustment. Tentori’s different findings may
be related to several cohort characteristics:
(1) The median time on hemodialysis before the first
vitamin D3 administration was significantly shorter (18 days)
compared with D2 analogs (37 days, Po0.0001).1 Assuming
that there is a survival advantage of any vitamin D compared
to no vitamin D at all, as found by the same authors1 and
others,3–5 the twice longer period of time without any
vitamin D in the D2 groups could have led to residual inferior
survival in this group to the extent that subsequent superior
survival of vitamin D2 administration was irreparably
mitigated.
(2) Prior to vitamin D analog administration, the D2
groups had significantly higher baseline serum calcium,
phosphorus, and PTH values, all of which are associated with
higher death risk.4,6
(3) Patients in D2 groups had significantly shorter follow-
up time when compared with the D3 group, as evident in the
Kaplan–Meier survival graphs.1 Longer cohort times could
have resulted in more consistent survival differences between
D2 and D3 groups.
Despite the foregoing and other limitations such as the
large proportion of African Americans and unusually large
number of patients who never received any vitamin D analog,
Tentori et al.1 still found a greater survival trend in the D2
(paricalcitol and doxercalciferol) groups compared with D3
(calcitriol) group. It would be interesting to know whether a
more commensurate comparison, for example, a matched
study that would only include patients with shorter pre-D2
period with lower serum minerals and PTH and longer
follow-up periods in the D2 groups as in the D3 group would
have resulted in even larger survival advantages of D2. The
Tentori study1 should still be considered as yet another
evidence that administration of any active vitamin D analog,
especially if D2, may confer improved survival to main-
tenance dialysis patients.
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We appreciate Dr Kalantar-Zadeh’s letter. Our study had
two major findings. First, mortality was reduced among
hemodialysis (HD) patients treated with intravenous
vitamin D. Second, the mortality risks associated with
administration of paricalcitol versus doxercalciferol were
similar.
Administration of paricalcitol and doxercalciferol was
associated with a significant survival benefit compared
with calcitriol only in the unadjusted model and in the
model adjusted for demographics. Dr Kalantar-Zadeh1
postulates that these findings reflect differences among
patients receiving the respective vitamin D preparations.
Time on HD before vitamin D administration was longer
in patients receiving paricalcitol (37 days) or doxercalci-
ferol (37 days) versus calcitriol (18 days). Baseline
concentrations of calcium (paricalcitol and doxercalciferol:
8.8 mg/dl; calcitriol: 8.5), phosphorus (paricalcitol and
doxercalciferol: 5.1 mg/dl; calcitriol: 5.0), and PTH (par-
icalcitol: 318; doxercalciferol: 335 pg/ml; calcitriol: 289)
were higher among patients receiving paricalcitol and
doxercalciferol versus calcitriol. However, it seems unlikely
that these modest differences were clinically significant.
Similar differences were observed by Teng et al.2 The
median follow-up times were longer among the calcitriol
(41 weeks) versus the paricalcitol (39 weeks) and
doxercalciferol (32 weeks) treated groups, but it is unlikely
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that these small differences biased our results. The most
likely explanation for our findings is that due to our
smaller sample size we had limited statistical power to
detect the 12–16% survival difference observed by Teng
et al.2 Only a prospective, randomized clinical trial can
provide conclusive evidence of the beneficial effect of a
given vitamin D analog relative to others currently
available.
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preventing contrast nephropathy:
Who is winner ?
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To the Editor: We read with interest the article by Dr P Liss
et al.1 They reported results contrary to that of our
RECOVER study and recent meta-analysis, which revealed
a lower incidence of contrast induced nephropathy (CIN) in
iodixanol than in ioxaglate users.2,3 We have some comments
and queries.
First, this different result may be attributed to the study
scheme itself. Our RECOVER study was a prospective
randomized controlled trial, but Dr P Liss’s was a retro-
spective study with many compounding factors influencing
the results.
Second, they did not present the most important risk
factors of CIN, basal serum creatinine and contrast dose.
They only briefly mentioned the data of 14% of patients
(8100 among 57 925 patients) and these data were recorded
in only a restricted period of 2005. They just reported the
mean and median values without depicting P-values.
Third, and most importantly, baseline characteristics of
the two groups were significantly different. The risk factors of
CIN – age, proportion of patients with diabetes, patients with
STEMI, unstable angina, proportion of patients receiving
PCI, previous renal failure, and previous dialysis – were
significantly different between the two groups.
We think that previous renal failure and previous dialysis
were the most critical determinants of developing CIN and
factors affecting clinical outcomes – re-hospitalization with a
renal failure and start of dialysis after angiography. These
were much more in the iodixanol group, which, we think,
might influence the result of poorer clinical outcomes of
iodixanol users.
We completely disagree with Dr P Liss et al. We think that
larger-scale long-term clinical data are necessary for solving
the important issue of which contrast medium is renal
protective.
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We thank Jo et al.1 for their thoughtful comments on our
manuscript. Indeed the outcome of our study sheds new
light on to the debate, which class of contrast media may
be best for avoiding renal failure.
Jo et al. feel that our study design, that is being
retrospective, may partly explain the outcome. Of course
the value of a study critically depends upon the design.
Optimal outcome can be expected for prospective rando-
mized studies with very large sample sizes. In this sense, all
studies focussing on contrast media and kidney function in
humans must be considered with caution: for instance, the
RECOVER2 study by Jo and co-workers, and the NEPH-
RIC3 study by Aspelin and co-workers were prospective
studies with 129 and 300 patients, respectively. In the study
discussed here,4 57 925 patients were evaluated on a
retrospective basis. Retrospective studies are widely in
use and provide valuable insight, such as the effectiveness
of vaccinations, only to mention one.
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